Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility trial of neoadjuvant apalutamide plus ADT before radical prostatectomy in locally advanced T4 high-risk prostate cancer
2021-003523-16Phase 2Active
- Sponsor
- Saarland University
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Saarland University. Primary endpoints: Proportion of patients with operability after induction treatment and Extension of induction therapy until PSA nadir. Started Sep 2021; status: active.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2021-003523-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003523-16.